Brilliance Tube for Tomorrows Effervescent Tablets
![](/46/pdcnewsitem/03/42/97/D2ll26gg3ZmqIYa.jpg)
With Brilliance, Sanner GmbH offers an expressive packaging solution for effervescent tablets. Drug producers can achieve higher attention and customer loyalty thanks to photorealistic printing and a wide range of design options. Patients profit from easy handling, while manufacturers can optimise their supply chain while ensuring the highest process safety.
Pain killers and other pharmaceutical agents can be easily digested and consumed in liquid form. Moreover, patients particularly appreciate the easy handling of effervescent tubes. Equipped with a convenience closure like the FOG from Sanner, the tubes remain tightly closed at all times, while the tablets are protected against light and moisture with a long shelf life. In contrast to blisters, for instance, the drugs remain inside their package, which in turn is not damaged during transport.
From a brand point of view, however, this packaging type has been reduced to its mere functionality and can rarely impress with an appealing design. For this reason, Sanner launched the Brilliance Tube last year. Apart from the optimal tablet protection, the development focused on the visual appearance. Compared with conventionally printed packages, the IML tubes offer a high-quality photorealistic printing with endless design varieties. Up to eight colors and metallic effects are available; the shock-proof and scratch-resistant material is extremely durable.
High Recognition Value, Safe Processes
“After the market launch we have already delivered the first Brilliance Tubes with the proven Sanner closures as complete solutions,” says Sanner CEO Holger Frank. “That way, customers can optimise their supply chains and make their daily work easier.” With its GMP-compliant, controlled production, Sanner complies with the highest hygiene standards. Moreover, the patented geometry of the tube base ensures high safety throughout the entire filling and packaging process. “Sanner customers receive everything from a single source — from the procurement of printed labels and manufacturing of decorated tubes to the delivery as system solution. If a customer wants the tubes to be child-resistant, we also have a solution to offer.”
Pharmaceutical manufacturers can bring their sales messages to life by choosing the ideal motif, conveying emotions without many words. They can design a consistent marketing concept with high recognition value — from print and online advertising to TV ads, as well as primary and secondary packaging. The visual messages can easily be transferred from the secondary to the primary packaging, so that patients can see the brand image at all times, either on their table or in the shelf. The excellent readability of the labels offers more room for product information, even on a small surface and with small fonts. This way, Brilliance unites high recognition value at point of sale with optimal consumer convenience and reliable filling processes.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance